Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 32.32 kDa 
• Atom Count: 2178 
• Residue Count: 252 
• Unique protein chains: 1

4Q9S

Crystal Structure of human Focal Adhesion Kinase (Fak) bound to Compound1 (3,5-DIHYDRO[1,2,4]TRIAZINO[3,4-C][1,4]BENZOXAZIN-2(1H)-ONE)

• DOI: 10.2210/pdb4Q9S/pdb

• Classification: Transferase/transferase inhibitor
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2014-05-01 Released: 2014-07-02 
• Deposition Author(s): Argiriadi, M.A., George, D.M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.07 Å
• R-Value Free: 0.216 
• R-Value Work: 0.176 
• R-Value Observed: 0.178 

Literature

Discovery of Selective and Orally Bioavailable Protein Kinase C theta (PKC theta ) Inhibitors from a Fragment Hit.

George, D.M., Breinlinger, E.C., Friedman, M., Zhang, Y., Wang, J., Argiriadi, M., Bansal-Pakala, P., Barth, M., Duignan, D.B., Honore, P., Lang, Q., Mittelstadt, S., Potin, D., Rundell, L., Edmunds, J.J.

(2015) J Med Chem 58: 222-236

• PubMed: 25000588 
• DOI: 10.1021/jm500669m
• Primary Citation of Related Structures:  
  4Q9Z, 4Q9S


• PubMed Abstract: 
  

Protein kinase Cθ (PKCθ) regulates a key step in the activation of T cells. On the basis of its mechanism of action, inhibition of this kinase is hypothesized to serve as an effective therapy for autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Herein, the discovery of a small molecule PKCθ inhibitor is described, starting from a fragment hit 1 and advancing to compound 41 through the use of structure-based drug design. Compound 41 demonstrates excellent in vitro activity, good oral pharmacokinetics, and efficacy in both an acute in vivo mechanistic model and a chronic in vivo disease model but suffers from tolerability issues upon chronic dosing.

---

Organizational Affiliation: 

AbbVie Bioresearch Center , 381 Plantation Street, Worcester, Massachusetts 01605, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Focal adhesion kinase 1	A	281	Homo sapiens	Mutation(s): 0  Gene Names: PTK2, FAK, FAK1 EC: 2.7.10.2
Find proteins for Q05397 (Homo sapiens) Explore Q05397  Go to UniProtKB:  Q05397
NIH Common Fund Data Resources
PHAROS  Q05397 GTEx  ENSG00000169398

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
30G	A	3,5-dihydro[1,2,4]triazino[3,4-c][1,4]benzoxazin-2(1H)-one C10 H9 N3 O2 PNPBXXNNLJGHBP-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
30G	IC50:  156000   nM  BindingDB
30G	IC50:  156000   nM  Binding MOAD

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.07 Å
• R-Value Free: 0.216 
• R-Value Work: 0.176 
• R-Value Observed: 0.178 
• Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 45.84	α = 90
b = 47.2	β = 99.32
c = 63.16	γ = 90

Software Package:

Software Name	Purpose
JDirector	data collection
PHASER	phasing
BUSTER	refinement
AutoPROC	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2014-05-01 
• Released Date: 2014-07-02 
Deposition Author(s): Argiriadi, M.A., George, D.M.

Revision History 

• Version 1.0: 2014-07-02
  Type: Initial release
  
• Version 1.1: 2014-07-30
  Changes: Database references
• Version 1.2: 2014-09-17
  Changes: Source and taxonomy
• Version 1.3: 2014-09-24
  Changes: Source and taxonomy
• Version 1.4: 2015-01-21
  Changes: Database references
• Version 1.5: 2017-11-22
  Changes: Refinement description